ReviewFrontiers in immunology2024
Gut microbiota: a crucial player in the combat against tuberculosis.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of tuberculosis and its treatment on the lung and gut microbiota: a global systematic review, meta-analysis, and amplicon-based metagenomic meta-analysis.BMC infectious diseases · 2025Pooled it
- Latent tuberculosis infection shapes gut microbiome and immune-metabolic interactions in people living with HIV.Gut microbes · 2026Article
- Gut-lung axis and microbiome alterations in mycobacterial infections: from pathogenesis to therapeutic potential.Gut microbes · 2026Review
- Cigarette smoke extract exposure induces gut microbial dysbiosis and impairs short-chain fatty acid metabolism in juvenile rats.Pediatric research · 2026Article
- Distinct Basal Gut Microbiota Profiles Are Associated with Strain-Specific Lung Responses toBiology · 2026Article
- Gut microbiota characteristics and its biological function analysis in patients with tuberculosis and diabetes mellitus co-morbidity.BMC microbiology · 2026Article
- Gut microbiota-driven immunomodulation in tuberculosis: targeting dysbiosis to overcome drug resistance.Frontiers in immunology · 2026Review
- Gut microbiota and tuberculosis.iMeta · 2025Review
- Respiratory diseases and the gut microbiota: an updated review.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mammalian gastrointestinal tract quickly becomes densely populated with foreign microorganisms shortly after birth, thereby establishing a lifelong presence of a microbial community. These commensal gut microbiota serve various functions, such as providing nutrients, processing ingested compounds, maintaining gut homeostasis, and shaping the intestinal structure in the host. Dysbiosis, which is characterized by an imbalance in the microbial community, is closely linked to numerous human ailments and has recently emerged as a key factor in health prognosis. Tuberculosis (TB), a highly contagious and potentially fatal disease, presents a pressing need for improved methods of prevention, diagnosis, and treatment strategies. Thus, we aim to explore the latest developments on how the host's immune defenses, inflammatory responses, metabolic pathways, and nutritional status collectively impact the host's susceptibility to or resilience against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.